FIELD: medicine.
SUBSTANCE: excitory cells of the immune system are recovered that is followed with primary incubation of the cells with an investigated substance to produce a primary-incubation supernatant or mixed cells and supernatant; secondary incubation of the target cells with the supernatant or mixed cells and supernatant wherein the secondary-incubation target cells are understood as human tumour cells or cell lines of an oncogenetic origins; the target cells are analysed where the analysis is specified in a group including an expression analysis of specific proteins and an apoptosis and/or necrosis analysis.
EFFECT: improvement of the method.
14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ALLOGENEIC ANTITUMOR THERAPEUTIC MEDICATION | 2004 |
|
RU2354694C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER USING ANTISENSE | 2018 |
|
RU2766457C2 |
| BIOLOGICAL MATERIALS AND APPLICATION THEREOF | 2006 |
|
RU2432363C9 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| HUMAN MELANOMA CELL LINE 26G WHICH SECRETES RECOMBINANT GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2395571C1 |
| HUMAN MELANOMA CELL LINE ILG WHICH SECRETES RECOMBINANT GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2395574C1 |
| HUMAN MELANOMA CELL LINE IG WHICH SECRETES RECOMBINANT GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2395572C1 |
| HUMAN MELANOMA CELL LINE PG WHICH SECRETES RECOMBINANT GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2395570C1 |
| HUMAN MELANOMA CELL LINE 31G WHICH SECRETES RECOMBINANT GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2395573C1 |
| Bcl-2 PROTEINS, FRAGMENTS THEREOF, AND APPLICATION THEREOF IN PATIENTS WITH MALIGNANT TUMOUR | 2004 |
|
RU2367468C2 |
